In today’s briefing:
- NIFTY Indices: Flows (Post Capping) At the Close Today; Round-Trip US$2.6bn
- UK Breaks Ground On First Tire To Fuel Facility Amid ELT Export Row
- Quiddity Leaderboard BSE/SENSEX Jun25: Some Names Are Still Close to the Border
- APL Apollo Tubes (APAT IN) Stepping up the Gas on Capacity Expansions
- Veeda Clinical Research Pre-IPO – Positioned for Growth Amid Financial Risks
NIFTY Indices: Flows (Post Capping) At the Close Today; Round-Trip US$2.6bn
- The NIFTY Index, Nifty Next 50 Index, Nifty Bank Index, Nifty IT Index, Nifty Midcap 150 Index, Nifty100 Low Volatility30 Index and the CPSE ETF rebalance at the close today.
- The round-trip trade across the indices is US$2.6bn and there are 26 stocks with over 1 day of ADV to trade from passive trackers.
- Stocks with the largest impact are Britannia Industries, Bharat Petroleum, Adani Total Gas, Indian Hotels, Jio Financial, IRCTC, Zomato, Federal Bank, Union Bank Of India and Crompton Greaves.
UK Breaks Ground On First Tire To Fuel Facility Amid ELT Export Row
- US$127 million tire recycling plant coming up in Sunderland
- TRA calls for immediate action to end the T8 exemption
- ATMA’s stress to rein in ELT imports comes as wakeup call for UK
Quiddity Leaderboard BSE/SENSEX Jun25: Some Names Are Still Close to the Border
- In this insight, we take a look at the Potential ADDs/DELs for the BSE SENSEX, BSE 100, and BSE 200 Indices in the June 2025 index rebal event.
- As things stand, there could be two index changes for the SENSEX index.
- There could be two ADDs/DELs for the BSE 100 index and eight ADDs/DELs for the BSE 200 index.
APL Apollo Tubes (APAT IN) Stepping up the Gas on Capacity Expansions
- APL Apollo has raised its capex guidance to accelerate growth in high-margin, value-added products (VAP) and new segments like heavy structural tubes, pre-engineered buildings, and solar structures.
- Margins have recovered from Q2 lows but remain subdued due to weak steel prices. Sales volumes have grown at an 18% CAGR.
- Trading at 65x TTM P/E vs. a 5-year average of 50x. A strong execution track record and RoCE >25% provide confidence in growth execution.
Veeda Clinical Research Pre-IPO – Positioned for Growth Amid Financial Risks
- Veeda Clinical Research Ltd (3340714Z IN) (VCRL) is planning to raise about US$115m in its upcoming India IPO.
- VCRL is a global contract research organization offering comprehensive drug development services, including non-clinical, pre-clinical, clinical trials, and studies across diverse drug types like generics, biosimilars, and medical devices.
- The company operates in key global markets, including North America, Europe, and Asia, with a presence in India.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
